Medical and health industry weekly report|The State Food and Drug Administration issued a key product information traceability announcement; Dingdang Kuaiyao completed a 1 billion yuan B+ round of financing_detailed interpretation_news_hot events_36氪
Random Tech News

Medical and health industry weekly report|The State Food and Drug Administration issued a key product information traceability announcement; Dingdang Kuaiyao completed a 1 billion yuan B+ round of financing_detailed interpretation_news_hot events_36氪

#Medical #health #industry #weekly #reportThe #State #Food #Drug #Administration #issued #key #product #information #traceability #announcement #Dingdang #Kuaiyao #completed #billion #yuan #financingdetailed #interpretationnewshot #events36氪

In recent years, innovations in the medical and health industry have continued to emerge and have developed into one of the most active industries. 36 krypton has witnessed and accompanied the growth of innovative companies in this field and brought professional voices to the industry.

To this end, 36Kr launched the “Medical and Health Industry Weekly Report”, which will be published regularly to provide readers with industry information from multiple perspectives such as capital, policy, finance, and new products.

Please check the weekly report of the medical and health industry on October 24. The industry weekly report contains the financing news reported by the “36Kr Venture Capital Channel” in the medical and health sector this week, as well as other domestic and foreign industry news that deserve attention.

Investment financing

36氪 learned that Hemu Bioengineering Co., Ltd. (hereinafter referred to as “Hemu Company”) has completed tens of millions of US dollars in Series B financing. This round of financing is led by Hillhouse Ventures, Legend Capital, Sanzheng Health Investment, etc. With the investment, Haoyue Capital acted as the exclusive financial advisor for this round of financing. The financing will be used to support the subsequent R&D and introduction of new products and accelerate the commercialization of products in the R&D pipeline to clinical and marketed products. Hemu Company is a platform company focusing on innovative solutions in the field of vascular intervention. Its current product line covers the treatment of diseases such as ischemic stroke, hemorrhagic stroke and intracranial vascular stenosis.

36氪 debut | “Hemu Company” received tens of millions of US dollars in Series B financing, Hillhouse Ventures led the investment

36 Krypton learned that the leading molecular diagnostic platform “Side Di Diagnosis” recently announced the completion of a new round of equity transactions of RMB 1.5 billion. This is also the second round of independent financing of Di Di Di Diagnosis after its spin-off from the Di Di Group. Prior to this, Siddi Diagnostics completed the first round of financing of 280 million yuan after the spin-off in 2019, and the new drug of Siddi has also completed the first round of US$140 million in funding after the spin-off. This round of financing of Siddi Diagnostics was led by CPE, with funds from CICC Capital, Jimin Credential, Qingsong Capital, Pudong Science and Technology, Haier Medical, Ruiyi Investment, and Lanshang Capital. Old shareholders Luxin Venture Capital, Shandong Transportation Development Fund and Xiantong Capital continued to increase their weight. Yikai Capital served as the exclusive financial advisor for this round of financing.

36 krypton debut | 1.5 billion new financing!Molecular diagnostic platform “Side Di Diagnostics” obtains a new round of equity financing

On October 20th, Chengdu Xilingyuan Pharmaceutical Co., Ltd. announced the completion of a 50 million yuan A round of financing. This round of financing was led by Shenzhen Sharing Zeshan Precision Medical Venture Capital Partnership, and Sichuan Health and Elderly Industry Equity Investment Fund Partnership. Follow the vote. It is reported that this round of financing funds will be mainly used to promote the company’s first innovative small molecule drug SMP-100-clinical research for the treatment of irritable bowel syndrome (IBS).

It is reported that “Dingdang Kuaiyao” has recently completed 1 billion yuan of B+ round financing. This round of financing was jointly invested by Taikang, Haier Medical, Longmen Investment and CMB International, CMB Telecom Fund, Sinopharm Zhongjin, Softbank China and other old shareholders. Huaxing Capital served as the exclusive financial advisor for this transaction. This round of financing will be mainly used to accelerate the urban layout of the company’s strategic project “Thousands of Cities and Wandians”, and 10 additional service cities will be opened by the end of 2020. “Dingdang Kuaiyao” is a new pharmaceutical retail enterprise. Through self-operated Dingdang smart pharmacy and self-built professional drug distribution team, it has established a model of “direct supply from pharmaceutical factories, delivery through online order stores, and pickup through online order stores” to provide large cities across the country The core area is open 7*24 hours, 1 minute to find a doctor, 28 minutes to deliver medicine to home.

Focusing on the new retail field of medicine and health, “Dingdang Kuaiyao” completed 1 billion yuan of B+ round of financing

It was learned on October 21 that Suzhou Jiesbyer Medical Technology Co., Ltd. announced the completion of tens of millions of RMB A+ round financing led by Daotong Capital, and Life Capital served as the exclusive financial advisor for this round of financing. The financing proceeds are mainly used to further enhance the company’s leading position in the complete set of spine endoscopy solutions, including expansion of production, new product registration, and market promotion.

It is reported that “Junling Technology” has recently completed tens of millions of yuan in Series A financing. The investor in this round is Sherpa Investment, and the funds raised will be mainly used for the company’s in-depth deployment in the health insurance field, including talent recruitment, technology research and development and market development. The full name of “Junling Technology” is Junling Health Management Consulting (Shanghai) Co., Ltd., which was established in January 2016 and is a third-party insurance technology and risk control service provider. The company mainly focuses on commercial personal health insurance, integrates high-quality medical service providers, establishes an intelligent operation and risk control platform, and provides products and risk control solutions for insurance companies and other related entities through a three-dimensional service network of “medicine, medicine and information” Program.

Focusing on insurance technology services, “Junling Technology” completed tens of millions of yuan in Series A financing

Acquisition and transfer

Haier Biomedical intends to use its own funds to acquire Chongqing Sanwei Pharmaceutical Co., Ltd. held by the natural person Mr. Zhong Shiliang through the newly established wholly-owned subsidiary Qingdao Haier Blood Technology Co., Ltd. (tentative name) at a consideration of RMB 5,472 million 90% equity of the company.

Policies and regulations

On October 17, the 22nd Meeting of the Standing Committee of the 13th National People’s Congress passed the Biosafety Law by voting. This law will come into effect on April 15, 2021. The Biosafety Law has perfected the basic system of biosafety risk prevention and control. Provides for the establishment of a biosafety risk monitoring and early warning system, a risk investigation and evaluation system, an information sharing system, an information release system, a directory and inventory system, a standard system, a biosafety review system, an emergency response system, an investigation traceability system, a national access system, and a major overseas biological system 11 basic systems including the security incident response system, the whole chain has built a “four beams and eight pillars” for biosecurity risk prevention and control.

It was learned on October 20 that the State Food and Drug Administration issued the “Announcement on Doing a Good Job in the Establishment of an Informatization Traceability System for Key Products”, requesting to actively promote the establishment of a drug informatization traceability system, improve the level and efficiency of drug supervision, and effectively ensure drug quality and safety . The “Announcement” pointed out that the holders of drug marketing authorization should implement the main responsibility of drug quality management in the whole process. The holders of the marketing authorization of key products such as selected varieties of national drug centralized procurement, narcotic drugs, psychotropic drugs, blood products, etc., must be in 2020 Before December 31, complete the construction of an informatized traceability system and collect traceability information throughout the entire process to basically realize the traceability of the above-mentioned four types of key varieties.

Product release approved

On October 19, Ali Health and Immunization Planning Center released the vaccine service platform 2.0. After logging in to the Yilu APP or Alipay Medical Health Channel, users can obtain professional vaccine content, get advice on child vaccination, quickly make reservations for community vaccination sites in some areas, and make online and offline vaccination appointments including HPV, flu vaccines, etc. Enjoy the intimate service of the whole process of vaccination.

On October 19, SenseTime launched the “SenseCare Smart Hospital Solution” for comprehensive hospital scenarios, with SenseCare® smart diagnosis and treatment platform and hospital smart operation systems as the core, and embedded AI technology through multiple scenario-based products In the hospital’s multi-departmental business system and multi-department clinical workflow, close collaboration and cross-platform linkage can be realized to improve hospital operation efficiency and medical service level.

On October 19, CStone Pharmaceuticals (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) granted its PD-L1 suglizumab (CS1001) orphan drug designation (ODD) for the treatment of T cell lymph tumor. This is the second orphan drug designation granted by the US FDA for its immunotherapy product line after the US FDA granted its anti-PD-1 monoclonal antibody CS1003 for the treatment of hepatocellular carcinoma in July this year.

On October 19, the official website of the State Food and Drug Administration showed that Sichuan Kelun Pharmaceutical Co., Ltd. was approved for production of moxifloxacin hydrochloride tablets declared for imitation of category 4 and deemed to have been reviewed. Moxifloxacin hydrochloride is an 8-methoxyfluoroquinolone broad-spectrum antibacterial drug with antibacterial activity. It is mainly used to treat upper and lower respiratory tract infections. At present, the main dosage forms of moxifloxacin hydrochloride that have been marketed in China are injections, tablets and eye drops.

On October 20, Jacos Pharmaceuticals announced that the US FDA has granted its original innovative drug JAB-3312 the orphan drug designation for the treatment of esophageal cancer, which can be used to support the global development of the drug for esophageal cancer indications. This is an allosteric protein tyrosine phosphatase (SHP2) inhibitor, which is the second self-designed and developed small molecule oral antineoplastic drug with global intellectual property rights for GACOS Pharmaceuticals. Prior to this, Jacos Pharmaceuticals and AbbVie (AbbVie) have reached a global strategic cooperation, which will obtain the exclusive license for the SHP2 project of Jacos Pharmaceuticals.

On October 21, Chengdu Kanghong Pharmaceutical issued an announcement stating that the company had received the “Notice of Drug Clinical Trial Approval” issued by the State Food and Drug Administration on Levominacipran Hydrochloride Sustained Release Capsules. Levomilnacipran Hydrochloride Sustained-Release Capsules is a serotonin and norepinephrine re-extraction inhibitor, suitable for the treatment of depression.

On October 22, AstraZeneca announced that the intelligent assisted non-small cell lung cancer PD-L1 interpretation “Immunohistochemical Digital Pathology Image Processing Software” developed in cooperation with Hangzhou Diyinga Technology Co., Ltd. has been approved by the Zhejiang Provincial Drug Administration The issued Class II medical device registration certificate became the first intelligent assisted non-small cell lung cancer PD-L1 interpretation software approved for clinical application in China.

Editor: Dun Yuting

36氪Pro is the WeChat public account of 36氪

.


Leave a Reply

Your email address will not be published. Required fields are marked *